Quinolone Antibiotics

• Overview
  
• Description of Products
  
  • Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
    
  • Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
    
  • Lomefloxacin (Maxaquin, Unimed)
    
  • Nalidixic (NegGram, Sanofi-Aventis)
    
  • Norfloxacin (Noroxin, Merck)
    
  • Ofloxacin (Floxin, Ortho-McNeil)
    
  • Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
    
  • Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
    
  • Gatifloxacin (Zymar, Allergan/Kyorin)
    
  • Trovafloxacin (Trovan, Pfizer)
  
  
  
• Generic Drug Impact and Availability
  
• Research and Development
  
• Market Size and Growth
  
• Competitive Analysis

Sulfonamide Antibiotics

• Overview
  
• Description of Products
  
• Sulfisoxazole (Gantrisin Pediatric, Roche)
  
  • Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
    
  • Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
    
  • Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)
  
  
  
• Research and Development
  
• Market Size and Growth
  
• Competitive Analysis

Tetracycline Antibiotics

• Overview
  
• Description of Products
  
• Generic Drug Impact and Availability
  
• Research and Development
  
• Market Size and Growth
  
• Competitive Analysis

Other Miscellaneous Antibiotics

• Overview
  
• Description of Products
  
• Aminoglycosides
  
  • Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
    
  • Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
    
  • Neomycin Sulfate (Neo-fradin, X Gen Pharms)
    
  • Streptomycin Sulfate (Streptomycin, Pfizer)
    
  • Lincomycin
    
  • Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
    
  • Chloramphenicol
    
  • Chloramphenicol (Chloromycetin,Pfizer)
    
  • Glycopeptide
    
  • Vancomycin (Vancocin, Viropharma)
    
  • Monobactams
    
  • Aztreonam (Azactam, Bristol-Myers Squibb)
    
  • Carbapenems
    
  • Imipenem/cilastatin (Primaxin, Merck)
    
  • Meropenem (Merrem, AstraZeneca)
    
  • Metronidazole
    
  • Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
    
  • Antituberculars
    
  • Rifampicin (Rifater, Sanofi-Aventis)
    
  • Capreomycin (Capastat sulfate, Eli Lilly & Co.)
    
  • Ethionamide (Trecator SC, Wyeth)
    
  • Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
    
  • Cycloserine (Seromycin, Eli Lilly & Co.)
    
  • Antileprotics
    
  • Dapsone (Dapsone, Jacobus)
    
  • Oxazolidinones
    
  • Linezolid (Zyvox, Pfizer)
    
  • Ketolides
    
  • Telithromycin (Ketek, Sanofi-Aventis)
    
  • Lipopeptides
    
  • Daptomycin (Cubicin, Cubist Pharmaceutical)
    
  • Glycyclines
    
  • Tigecycline (Tygacil, Wyeth)
    
    
  • Generic Drug Impact and Availability
    
  • Research and Development
    
  • Market Size and Growth
    
  • Competitive Analysis

Corporate Profiles

• Introduction
  
• Abbott Laboratories
  
• AstraZeneca plc
  
• Bayer Schering Pharma AG
  
• Cubist Pharmaceuticals, Inc
  
• Daiichi Sankyo Co., Ltd.
  
• GlaxoSmithKline
  
• Johnson & Johnson Group
  
• King Pharmaceuticals, Inc.
  
• Merck & Company, Inc.
  
• Pfizer, Inc.
  
• Roche
  
• Sanofi-Aventis
  
• Wyeth

Company Names and Addresses

Volume III: Antivirals

Chapter One: Executive Summary

• Introduction
  
• Scope and Methodology
  
• Size and Growth of the Market
  
• Issues and Trends Affecting Market
  
• Leading Competitors

Chapter Two: Introduction

• Introduction to Viruses
  
  • Examples of Pathogenic Viruses
  
  
  
• Virus Function and Life History
  
  • Replication in DNA Viruses
    
  • Replication of RNA Viruses
    
  • Replication in Retroviruses
  
  
  
• Host Defenses Against Viruses
  
• Viral Ploys to Invade Host Cells and Circumvent Host Responses
  
  • Invasion of Host Cells
    
  • Subversion of the Immune Response
    
  • Avoidance of Immune Detection and Attack by Killer Cells
  
  
  
• HIV and AIDS
  
• Demographics and Epidemiology
  
  • Cytomegalovirus
    
  • Hepatitis B Virus
    
  • Hepatitis C Virus (HCV)
    
  • Herpes
    
  • Human Immunodeficiency Virus (HIV)
    
  • Human Papillomavirus (HPV)
    
  • Influenza
    
  • Respiratory Syncytial Virus (RSV)
    
  • Population Demographics

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors

• Overview
  
• Description of Products
  
  • Nucleoside Reverse Transcriptase Inhibitors
    
  • Zidovudine (Retrovir, GlaxoSmithKline)
    
  • Didanosine (Videx, Bristol-Myers Squibb)
    
  • Zalcitabine (Hivid, Roche)
    
  • Lamividine(Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
    
  • Stavudine (Zerit, Bristol-Myers Squibb)
    
  • Abacavir (Ziagen, GlaxoSmithKline)
    
  • Nucleotide Analogue Reverse Transcriptase Inhibitors
    
  • Tenofovir (Viread, Gilead Sciences)
    
  • Adefovir dipivoxil (Hepsera, Gilead Sciences)
    
  • Combination Nucleoside Reverse Transcriptase Inhibitors
    
  • Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)
    
  • Abacavir and Lamivudine (Kivexa, GlaxoSmithKline)
    
  • Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
    
  • Non-Nucleoside Reverse Transcriptase Inhibitors
    
  • Nevirapine (Viramune, Boehringer Ingelheim)
    
  • Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
    
  • Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
    
  • Emtricitabine (Emtriva, Gilead Sciences)
    
  • DNA Polymerase Inhibitors
    
  • Acyclovir (Zovirax, GlaxoSmithKline)
    
  • Valacyclovir (Valtrex, GlaxoSmithKline)
    
  • Famciclovir (Famvir, Novartis)
    
  • Penciclovir (Denavir, Novartis)
    
  • Ganciclovir (Cytovene, Roche)
    
  • Ribavirin (Virazole, ICN Pharmaceuticals)
    
  • Foscarnet (Foscavir, AstraZeneca)
    
  • Valganciclovir (Valcyte, Hoffman-LaRoche)
    
  • Cidofovir (Vistide, Gilead Sciences)
  
  
  
• Research and Development
  
  • Baraclude
    
  • Truvada
    
  • Telbivudine
    
  • Viramidine
    
  • Capravirine
    
  • Elvucitabine
    
  • Epzicom
    
  • Etravirine (TMC125)
    
  • GW5634
    
    
  • MIV 150
    
  • Pradefovir
    
  • Reverset
    
  • TMC278
    
  • Valopicitabine
    
  • Valtorcitabine
    
  • BILR 355
    
  • Calanolide A
    
  • DPC 961 and DPC 963
    
  • GW8248
    
  • MCC-478
    
  • MIV-310
  
  
  
• Market Size and Growth
  
• Competitive Analysis

Chapter Four: Protease Inhibitors

• Overview
  
• Description of Products
  
  • Single Agents
    
  • Saquinavir (Fortovase, Hoffman-LaRoche; Invirase, Hoffman-LaRoche)
    
  • Nelfinavir (Viracept, Agouron Pharmaceuticals)
    
  • Indinavir (Crixivan, Merck)
    
  • Ritonavir (Norvir, Abbott Laboratories)
    
  • Amprenavir (Agenerase, GlaxoSmithKline
    
  • Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
    
  • Atazanavir (Reyataz, Bristol-Myers Squibb)
    
  • Combination Protease Inhibitors
    
  • Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)
  
  
  
• Research and Development
  
  • Tipranavir (PNU-140690)
    
  • GW640385 (VX-385)
    
  • TMC-114
    
  • BMS232632
    
  • RO033-4649
    
  • VX-950
  
  
  
• Market Size and Growth
  
• Competitive Analysis

Chapter Five: Other Antivirals

• Overview
  
• Description of Products
  
  • Aldara
    
  • CytoGam
    
  • Flumadine
    
  • Fuzeon
    
  • Infergen
    
  • Pegasys
    
  • Pegasys + Copegus
    
  • Rebetol, Rebetron
    
  • Relenza
    
  • RespiGam
    
  • Symmetrel
    
  • Synagis
    
  • Tamiflu
    
  • Vistide
  
  
  
• Research and Development
  
  • Attachment and Fusion Inhibitors
    
  • Gene Therapies
    
  • Integrase Inhibitors
    
  • Maturation Inhibitors
    
  • Zinc Finger Inhibitors
    
  • Antisense Drugs
    
  • Cytokines
    
  • Other
  
  
  
• Market Size and Growth
  
• Competitive Analysis

Chapter Six: Issues and Trends

• Introduction
  
• Antiviral Drug Resistance
  
• HIV Drug Cost Controversy
  
• Antiretroviral Treatment Regimens
  
• HIV and Women
  
• Global Surveillance
  
  
• Biochemical Prevention and Treatment of Viral Infections
  
• New Treatment for Hepatitis C
  
• Costs and Funding of HIV Treatment
  
• Access to HIV/AIDS Treatment

Chapter Seven: Total Market Size and Forecast

• Overview
  
• Total Market Size and Forecast

chapter Eight: Corporate Profiles

• Introduction
  
• Abbott Laboratories
  
• Boehringer Ingelheim GmbH
  
• Bristol-Myers Squibb Company
  
• Gilead Sciences, Inc.
  
• GlaxoSmithKline
  
• MedImmune, Inc.
  
• Merck & Company, Inc.
  
• Novartis Pharmaceuticals Corporation
  
• Roche
  
• Schering-Plough Corporation

APPENDIX: Company Names and Addresses






List of Exhibits



Chapter One: Executive Summary

• Table 7-1: The World Market for Antiviral Drugs 2002-2009
  
• Figure 7-1: The World Market for Antiviral Drugs 2002-2009

Chapter Two: Introduction

• Table 2-1: Host Cell Receptors
  
• Table 2-1: Estimated World and U.S. Incidence of Viral Infections
  
• Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
  
• Table 2-2: World Population by Selected Geographical Region, 2004-2050
  
• Figure 2-2: World Population by Selected Geographical Region, 2003-2050
  
• Table 2-3: Estimated World Population by Age and Geographical Region, 2004
  
• Figure 2-3: Estimated World Population by Age and Geographical Region, 2004

Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors

• Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors
  
• Table 3-2: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors
  
• Table 3-3: Currently Available DNA Polymerase Inhibitors
  
• Table 3-4: Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors in Development (Product, Developer, Phase)
  
• Table 3-5: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2002-2009
  
• Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2002-2009
  
• Table 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2004
  
• Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2004
  
• Table 3-7: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2004
  
• Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2004
  
• Table 3-8: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
  
• Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2004
  
• Table 3-9: Estimated Sales and Market Share of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2004
  
• Figure 3-5: Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2004

Chapter Four: Protease Inhibitors

• Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
  
• Table 4-2: Protease Inhibitors in Development (Product, Developer, Phase, Earliest Approval Date)
  
• Table 4-3: The Market for Protease Inhibitors 2002-2009
  
• Figure 4-1: Protease Inhibitor Market 2002-2009
  
• Table 4-4: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2004
  
• Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2004
  
• Table 4-5: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2004
  
• Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2004
  
• Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2004
  
• Figure 4-4: Protease Inhibitor Market Estimated Market Share of Top Protease Inhibitors, 2004

Chapter Five: Other Antivirals

• Table 5-1: Currently Available Other Antivirals (Type, Brand, and Manufacturer)
  
• Table 5-2: Other Antivirals in Development (Product, Developer, Phase, Earliest Approval Date)
  
• Table 5-3: The Market for Other Antivirals 2002-2009
  
• Figure 5-1: The Market for Other Antivirals 2002-2009
  
• Table 5-4: The Market for Other Antivirals Estimated Products Sales by Infection Type, 2004
  
• Figure 5-2: The Market for Other Antivirals Market Share by Infection Type, 2004
  
• Table 5-5: The Market for Other Antivirals Estimated Products Sales by Geographic Region, 2004
  
• Figure 5-3: The Market for Other Antivirals Market Share by Geographic Region, 2004
  
• Table 5-6: The Market for Other Antivirals Estimated Revenues and Market Share of Leading Suppliers 2004
  
• Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2004
  
• Table 5-7: Other Antiviral Market Estimated Sales of Other Antiviral Products 2004
  
• Figure 5-5: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2004

Chapter Six: Issues and Trends

• Table 6-1: Women (15 to 49) Living with HIV/AIDS by Region 2004
  
• Table 6-2: Funding for HIV/AIDS
  
• Table 6-3: Access Needs of Adults and Children with HIV by Region 2004
  
• Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region in the Developing World

Chapter Seven: Total Market Size and Forecast

• Table 7-1: The World Market for Antiviral Drugs 2002-2009
  
• Figure 7-1: The World Market for Antiviral Drugs 2002-2009
  
• Table 7-2: World Market for Antiviral Drugs by Type 2002-2009
  
• Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2002-2009

Abstract

• Antifungals
• Antibacterials
• Antivirals

• Epidemiology including Incidence Statistics for each type of infection.
• Current Market Size and Revenue Forecasts for each market segment to assist with long term planning.
• Discussion of Competitive Products in the market and new products in the delivery pipeline.
• Coverage of Generic Threats for affected major products.
• Round-Up of the Key Players in each area of anti-infectives.
• Over 195 Tables and Figures for easy access to information and decision support tools, internal emails, memos and presentations.
• Discussion of Unique Issues and Emerging Trends for each antibiotic area.
• Market Share of Leading Competitors for each area.
• U.S., Europe, Japan and Rest of World market data.